NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Unconfirmed

**Date:** Wednesday 4 October 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Charles Crawley (Chair) Present for all items
2. Baljit Singh (Vice-chair) Present for all items
3. Dr Hatim Abdulhussein Present for all items
4. Professor Iolo Doull Present for all items
5. Dr Francis Drobniewski Present for all items
6. Dr Bushra Hasnie Present for all items
7. Dr Warren Linley Present for all items
8. Dr Andrew Makin Present for all items
9. Dr Rhiannon Owen Present for all items
10. Professor David McAllister Present for all items
11. Mariana Bacelar Items 5.1 to 5.3.2
12. Anna Pracz Present for all items
13. Gabriel Rogers  Present for all items
14. Dr Toby Smith Present for all items
15. Mary Weatherstone Present for all items
16. Nigel Westwood Present for all items
17. Peter Wheatley-Price Present for all items
18. Dr Stuart Williams Present for all items
19. Tony Wootton Present for all items
20. Vanessa Danielson Present for all items

NICE staff (key players) present

Richard Diaz, Associate Director Items 1.1 to 4.3.2

Vonda Murray, Project Manager Items 1.1 to 4.3.2

Ian Watson, Associate Director Items 5.1 to 5.3.2

Jeremy Powell, Project Manager Items 5.1 to 5.3.2

Gorge Millington, Heath Technology Assessment Advisor Items 1.1 to 4.3.2

Alan Moore, Heath Technology Assessment Analyst Items 1.1 to 4.3.2

Eleanor Donegan, Heath Technology Assessment Adviser Items 5.1 to 5.3.2

Cara Gibbons, Heath Technology Assessment Analyst Items 5.1 to 5.3.2

External assessment group representatives present

Claire Rothery, University of York Items 1.1 to 4.1.3

Mark Corbett, University of York Items 1.1 to 4.1.3

Noortje Uphoff, University of York Items 5.1 to 5.1.3

Matthew Walton, University of York Items 5.1 to 5.1.3

Clinical, Patient & NHS England experts present

Sailaja Maganti, Patient expert, nominated by Nodular Prurigo International Items 1.1 to 4.1.3

Rachel Hardwick, Patient expert, nominated by Nodular Prurigo International Items 1.1 to 4.1.3

Philip Laws, Consultant Dermatologist, Clinical expert, nominated by Sanofi Items 1.1 to 4.1.3

Anthony Bewley, Consultant Dermatologist, Clinical expert, nominated by British Association of Dermatologists Items 1.1 to 4.1.3

Peter Clark, CDF Clinical Lead Items 5.1 to 5.3.2

Lizzie Ellis, Patient expert, nominated by xxx Items 5.1 to 5.1.3

David Kinsey, Patient expert, Nominated by Prostate Cancer UK Items 5.1 to 5.1.3

Professor Noel Clarke, Clinical expert, Professor of Urological Oncology, nominated by AstraZeneca Items 5.1 to 5.1.3

Professor Suneil Jain, Clinical expert, Professor of Clinical Oncology and Honorary Consultant in Clinical Oncology, nominated by AstraZeneca Items 5.1 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Dr Veline L’Esperance.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 6 September 2023.

1. Appraisal of [Dupilumab for treating prurigo nodularis [ID4054]](https://www.nice.org.uk/guidance/indevelopment/gid-ta11081)
   1. Part 1 – Open session
      1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AstraZeneca.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11081).
      3. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by Charles Crawley.
   2. Part 2 –Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
      1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus..
      2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.

* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11081>.

1. **Appraisal of** **[Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer ID3920](https://www.nice.org.uk/guidance/indevelopment/gid-ta10802)** 
   1. Part 1 – Open session
      1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Sanofi.
      2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10802).
      3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Nigel Westwood (Lay), Iolo Doull (Clinical), Peter Wheatley-Price (Cost)
   2. Part 2a – Closed session (members of the public, company representatives, patient and clinical experts were asked to leave the meeting).
      1. The committee discussed confidential information submitted for this item.
   3. Part 2b – Closed session
      1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus..
      2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.

* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10802>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 26th October 2023 and will start promptly at 9:00am.